Review Highlights ctDNA's Role in Early Cancer Relapse Detection

A JAMA review indicates that circulating tumor DNA (ctDNA) can detect cancer relapse months earlier in patients with stage II colon cancer and muscle-invasive bladder cancer. This advancement could inform post-surgery treatment decisions, though its broader utility for guiding earlier therapy in other contexts is still under evaluation.